title: Pharmacokinetics, pharmacodynamics, and clinical efficacy of albuterol RespiClick(™) dry-powder inhaler in the treatment of asthma.
abstract: BACKGROUND
  Incorrect use of inhaler devices by patients with asthma is common and can adversely affect clinical outcomes. Devices that are straightforward to use are less likely to result in dosing errors and can improve patients' satisfaction with therapy and adherence. A novel dry-powder formulation of the rescue bronchodilator albuterol (salbutamol) administered using a multidose dry-powder inhaler (mDPI; RespiClick™) has recently been approved in the USA.
  
  
  METHODS
  Studies on the albuterol mDPI were identified in searches of PubMed and www.clinicaltrials.gov . Pharmacokinetic, pharmacodynamic, efficacy, and safety data, and patients' experiences with the albuterol mDPI are presented.
  
  
  CONCLUSIONS
  The albuterol mDPI has an efficacy/tolerability profile consistent with other inhaled forms of albuterol, and is reliable, easy to use, and associated with a high level of patient satisfaction. This is the first albuterol dry-powder inhaler (DPI) to become available in the USA, with most other formulations being delivered using a pressurized metered-dose inhaler (pMDI). The availability of a breath-actuated device avoids the challenge of coordinating actuation and breathing when using pMDIs, and could simplify treatment for patients also using a DPI for controller medication. Additional features of RespiClick, such as an integrated dose counter and minimal pre-inhalation preparation, facilitate its use.
authors.affiliation: a University of California , School of Medicine , San Diego , CA , USA.|b Allergy & Asthma Medical Group & Research Center , San Diego , CA , USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Welch
mesh_terms: D000280:Administration, Inhalation; D000420:Albuterol / Q000008:administration & dosage* / Q000493:pharmacokinetics; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D017277:Drug Approval; D058995:Dry Powder Inhalers; D006801:Humans; D055118:Medication Adherence; D017060:Patient Satisfaction; D014481:United States
chemical_list: D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D000420:Albuterol
keywords: Albuterol; RespiClick; asthma; breath-actuated; bronchodilation; multidose dry-powder inhaler; rescue inhaler; salbutamol; short-acting beta-agonist